151 related articles for article (PubMed ID: 32875487)
1. Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection.
Kuwatsuka Y; Atsuta Y; Hirakawa A; Uchida N; Inamoto Y; Najima Y; Ikegame K; Eto T; Ozawa Y; Ichinohe T; Inoue M; Kimura T; Okamoto S; Miyamura K; Fukuda T
Int J Hematol; 2020 Dec; 112(6):841-850. PubMed ID: 32875487
[TBL] [Abstract][Full Text] [Related]
2. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
Avery RK; Bolwell BJ; Yen-Lieberman B; Lurain N; Waldman WJ; Longworth DL; Taege AJ; Mossad SB; Kohn D; Long JR; Curtis J; Kalaycio M; Pohlman B; Williams JW
Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
[TBL] [Abstract][Full Text] [Related]
5. Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.
Iida M; Fukuda T; Ikegame K; Yoshihara S; Ogawa H; Taniguchi S; Takami A; Abe Y; Hino M; Etou T; Ueda Y; Yujiri T; Matsui T; Okamura A; Tanaka J; Atsuta Y; Kodera Y; Suzuki R
Int J Hematol; 2011 Apr; 93(4):523-531. PubMed ID: 21465117
[TBL] [Abstract][Full Text] [Related]
6. [Clinical analysis of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
Guo Z; Chen HR; Liu XD; Bian JM; He XP; Lou JX; Chen P; Yang K; Liu D; Zhang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):971-4. PubMed ID: 22931666
[TBL] [Abstract][Full Text] [Related]
7. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
[TBL] [Abstract][Full Text] [Related]
8. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation.
Crippa F; Corey L; Chuang EL; Sale G; Boeckh M
Clin Infect Dis; 2001 Jan; 32(2):214-9. PubMed ID: 11170910
[TBL] [Abstract][Full Text] [Related]
9. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
10. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus disease after hematopoietic cell transplantation: A Japanese transplant registry analysis.
Inamoto Y; Takeda W; Hirakawa T; Sakaguchi H; Nakano N; Uchida N; Doki N; Ikegame K; Katayama Y; Sawa M; Kuriyama T; Hiramoto N; Ota S; Ozawa Y; Kataoka K; Kanda Y; Hino M; Kimura T; Atsuta Y; Fukuda T; Nagafuji K
Am J Hematol; 2022 Dec; 97(12):1568-1579. PubMed ID: 36087061
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
15. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
Transplantation; 1996 Aug; 62(3):376-80. PubMed ID: 8779686
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
Ehlert K; Groll AH; Kuehn J; Vormoor J
Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.
Iida M; Fukuda T; Uchida N; Murata M; Aotsuka N; Minagawa K; Oohashi K; Fukushima K; Kondo T; Eto T; Miyamoto T; Morishima Y; Nagamura T; Atsuta Y; Suzuki R
Clin Transplant; 2014 Sep; 28(9):980-9. PubMed ID: 24943923
[TBL] [Abstract][Full Text] [Related]
19. Management of graft-versus-host disease.
Arai S; Vogelsang GB
Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
[TBL] [Abstract][Full Text] [Related]
20. A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT.
Schäfer H; Blümel-Lehmann J; Ihorst G; Bertz H; Wäsch R; Zeiser R; Finke J; Marks R
Ann Hematol; 2021 Aug; 100(8):2095-2103. PubMed ID: 33755792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]